🔗 Share this article

While the United States proceeds with sweeping adjustments to its immunization guidelines, an unexpected name appears in a surprising turn: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines during the global health crisis and has zeroed in on possible fatalities after Covid immunization in her brief time at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities planned to announce major revisions to the pediatric immunization program recently, synchronizing the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US out of step with many the international standard with insufficient data for benefit. The announcement has been postponed until the new year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

Consolidating Power at the Regulatory Body

This interim role may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Høeg has repeatedly called for discontinuing certain pediatric shot schedules in the US to become more in line with Denmark's approach, a country with universal health coverage and a population approximately the size of Wisconsin’s.

So far statements, she has continued to focus on immunizations – typically the domain of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Background

Høeg has no apparent experience in medication creation, approval processes or leadership, which has been customary for previous heads of the biologics center. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a large organization. She is not an expert in industry regulation.”

Former heads of CBER would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she lacks the kind of background that prior appointees who led CBER have had.”

This division has an immense portfolio at the FDA, she emphasized.

“Many people just focuses on the novel medication approvals, but the generic drug division approves numerous generic drugs. There’s a biosimilars program, OTC medication office and more, and all of those need to be supervised,” Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant management component to the job, which manages in excess of 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” she added.

Agency Reaction and Controversial Initiatives

In response to questions about Dr. Høeg's qualifications and whether this assignment signifies increased cooperation among regulatory chiefs on vaccines, a spokesperson responded that the “questions stem from flawed presumptions”.

“Her experience matches the duties of her job,” the official stated, pointing to the time Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious one-day drug-approval program that apparently worried her former heads. “By what process are these drugs being selected for this expedited pathway? Who makes the calls?” Howard said. “There is a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards laxer regulations of pharmaceuticals, with the exception of immunizations.”

Public History on Vaccines

Regarding vaccines, Høeg has a more established, if troubling, past, some experts observe. She published a analysis using unverified public submissions to determine the frequency of heart inflammation after Covid immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming government encompassed changing rules for new vaccines and discontinuing “optional” immunizations, she remarked after the election on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of excluding young men from getting COVID-19 vaccinations.

“She is an complete ideologue who commences with her conclusions and tailors the evidence to retrofit the evidence in a very misleading, fraudulent manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|